Asieris Receives Approval in Australia for Phase I Study of APL-2401 in Patients with FGFR2/3-Driven Advanced Solid Tumors

Shanghai, China, January 22, 2026 — Asieris Pharmaceuticals (Stock Code: 688176.SH), a global innovative pharmaceutical company focused on genitourinary tumors and women’s health, announces that it has received approval from a Human Research Ethics Committee in Australia and has completed clinical trial notification with the Therapeutic Goods Administration to initiate a Phase I clinical study of […] The post Asieris Receives Approval in Australia for Phase I Study of APL-2401 in Patients with FGFR2/3-Driven Advanced Solid Tumors appeared first on Asieris Pharmaceuticals .